SRR8518367
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.770
- INTERFERON_GAMMA_RESPONSE+0.660
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.410
- G2M_CHECKPOINT+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- E2F_TARGETS+0.390
- COMPLEMENT+0.360
- PANCREAS_BETA_CELLS+0.310
Top 10 suppressed
- ADIPOGENESIS-0.360
- NOTCH_SIGNALING-0.330
- ESTROGEN_RESPONSE_EARLY-0.320
- BILE_ACID_METABOLISM-0.300
- MYOGENESIS-0.280
- ANDROGEN_RESPONSE-0.240
- CHOLESTEROL_HOMEOSTASIS-0.240
- FATTY_ACID_METABOLISM-0.240
- MYC_TARGETS_V2-0.240
- PROTEIN_SECRETION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR29022833 | — | D | 0.895 |
| 2 | C3N-02922 | — | cohortMD2 | 0.845 |
| 3 | R217 | — | — | 0.826 |
| 4 | MBCProject_0246_T1_RNA | — | D | 0.826 |
| 5 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.814 |
| 6 | SRR8518190 | — | D | 0.813 |
| 7 | AUR-AFE5-TTP1-A-1-0-R-A741-41 | — | D | 0.810 |
| 8 | 2dbf638a-46c1-4ec8-b81d-d859c7dcf989 | — | — | 0.804 |
| 9 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.804 |
| 10 | SRR5903558 | — | cohortMD2 | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.770 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.660 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |